ARID1A and cancer: Given that most of the current synthetic lethal interactions have been based on the functional associations and phenotypic observations, more in-depth mechanistic understanding will continue to provide key insights into how the differential susceptibility of cancer cells and various immune cells to ARID1A deficiency promotes or suppresses antitumor immunity.